3/14/2024 0 Comments Pardes biosciences![]() Pardes anticipates using its platform to develop new drug candidates in the future to treat diseases with greater unmet medical needs. The drug was well-tolerated in toxicity studies. PBI-0451 was demonstrated to hinder replication of various coronaviruses such as SARS-CoV-2 across several in-vitro models in preclinical studies. Pardes Biosciences announced the initiation of a Phase 1 clinical trial, evaluating the companys lead candidate, PBI-0451 which is being developed as a. The company expects to report results from the Phase I trial in the fourth quarter of this year. “This trial marks a significant milestone in our efforts to develop PBI-0451 as a potential oral antiviral therapy for SARS-CoV-2, and we look forward to providing updates on our progress.” The company leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery, enabling clients to get oral. Pardes Biosciences CEO Uri Lopatin said: “We believe oral anti-viral therapies have the potential to address the significant global public health challenges of both Covid-19 as well as future pandemics. ![]() It will enrol up to a total of 110 participants and will evaluate the drug-to-drug interaction potential of the oral antiviral.įurthermore, the trial intends to assess the possibility of dosing PBI-0451 as a once- or twice-daily pill. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |